Neural Stem Cells and Human induced pluripotent stem cells to model rare CNS diseases

Lidia De Filippis, Cristina Zalfa, Daniela Ferrari

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite the great effort spent over the last decades to unravel the pathological mechanisms underpinning the development of central nervous system disorders, most of them remain still unclear. In particular, the study of rare brain diseases is hurdled by the lack of post-mortem samples and of reliable epidemiological studies, thus the setting of in vitro modeling systems appears essential to dissect the puzzle of genetic and environmental alterations affecting neural cells viability and functionality The isolation and expansion in vitro of embryonic (ESC) and fetal neural stem cells (NSC) from human tissue has efficiently allowed to model several neurological diseases "in a dish" and has also provided a novel platform to test potential therapeutic strategies in a pre-clinical setting. In the recent years, the development of induced pluripotent stem cell (iPS) technology, has added enormous value to the aforementioned approach thanks to their capability for generating disease-relevant cell phenotypes in vitro and to their perspective use in autologous transplantation. However, while the potentiality of ESC, NSC and iPS has been widely sponsored, the pitfalls related to the available protocols for differentiation and the heterogeneity of lines deriving from different individuals have been poorly discussed. Here we present pro and contra of using ESC, NSC or iPS for modeling rare diseases like Lysosomal Storage disorders (LSDs) and Motor Neuron Syndromes (MNS). In this view, the advent of gene editing technologies is a unique opportunity to standardize the data analysis in preclinical studies and to tailor clinical protocols for stem cell-mediated therapy.

Original languageEnglish
JournalCNS and Neurological Disorders - Drug Targets
DOIs
Publication statusE-pub ahead of print - Jun 15 2017

Fingerprint

Induced Pluripotent Stem Cells
Neural Stem Cells
Central Nervous System Diseases
Rare Diseases
Neurological Models
Fetal Stem Cells
Technology
Autologous Transplantation
Brain Diseases
Motor Neurons
Clinical Protocols
Cell- and Tissue-Based Therapy
Epidemiologic Studies
Cell Survival
Stem Cells
Phenotype
In Vitro Techniques
Therapeutics

Keywords

  • Journal Article

Cite this

Neural Stem Cells and Human induced pluripotent stem cells to model rare CNS diseases. / De Filippis, Lidia; Zalfa, Cristina; Ferrari, Daniela.

In: CNS and Neurological Disorders - Drug Targets, 15.06.2017.

Research output: Contribution to journalArticle

@article{3ab02579b89a462cb7ef0448b6436772,
title = "Neural Stem Cells and Human induced pluripotent stem cells to model rare CNS diseases",
abstract = "Despite the great effort spent over the last decades to unravel the pathological mechanisms underpinning the development of central nervous system disorders, most of them remain still unclear. In particular, the study of rare brain diseases is hurdled by the lack of post-mortem samples and of reliable epidemiological studies, thus the setting of in vitro modeling systems appears essential to dissect the puzzle of genetic and environmental alterations affecting neural cells viability and functionality The isolation and expansion in vitro of embryonic (ESC) and fetal neural stem cells (NSC) from human tissue has efficiently allowed to model several neurological diseases {"}in a dish{"} and has also provided a novel platform to test potential therapeutic strategies in a pre-clinical setting. In the recent years, the development of induced pluripotent stem cell (iPS) technology, has added enormous value to the aforementioned approach thanks to their capability for generating disease-relevant cell phenotypes in vitro and to their perspective use in autologous transplantation. However, while the potentiality of ESC, NSC and iPS has been widely sponsored, the pitfalls related to the available protocols for differentiation and the heterogeneity of lines deriving from different individuals have been poorly discussed. Here we present pro and contra of using ESC, NSC or iPS for modeling rare diseases like Lysosomal Storage disorders (LSDs) and Motor Neuron Syndromes (MNS). In this view, the advent of gene editing technologies is a unique opportunity to standardize the data analysis in preclinical studies and to tailor clinical protocols for stem cell-mediated therapy.",
keywords = "Journal Article",
author = "{De Filippis}, Lidia and Cristina Zalfa and Daniela Ferrari",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2017",
month = "6",
day = "15",
doi = "10.2174/1871527316666170615121753",
language = "English",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Neural Stem Cells and Human induced pluripotent stem cells to model rare CNS diseases

AU - De Filippis, Lidia

AU - Zalfa, Cristina

AU - Ferrari, Daniela

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2017/6/15

Y1 - 2017/6/15

N2 - Despite the great effort spent over the last decades to unravel the pathological mechanisms underpinning the development of central nervous system disorders, most of them remain still unclear. In particular, the study of rare brain diseases is hurdled by the lack of post-mortem samples and of reliable epidemiological studies, thus the setting of in vitro modeling systems appears essential to dissect the puzzle of genetic and environmental alterations affecting neural cells viability and functionality The isolation and expansion in vitro of embryonic (ESC) and fetal neural stem cells (NSC) from human tissue has efficiently allowed to model several neurological diseases "in a dish" and has also provided a novel platform to test potential therapeutic strategies in a pre-clinical setting. In the recent years, the development of induced pluripotent stem cell (iPS) technology, has added enormous value to the aforementioned approach thanks to their capability for generating disease-relevant cell phenotypes in vitro and to their perspective use in autologous transplantation. However, while the potentiality of ESC, NSC and iPS has been widely sponsored, the pitfalls related to the available protocols for differentiation and the heterogeneity of lines deriving from different individuals have been poorly discussed. Here we present pro and contra of using ESC, NSC or iPS for modeling rare diseases like Lysosomal Storage disorders (LSDs) and Motor Neuron Syndromes (MNS). In this view, the advent of gene editing technologies is a unique opportunity to standardize the data analysis in preclinical studies and to tailor clinical protocols for stem cell-mediated therapy.

AB - Despite the great effort spent over the last decades to unravel the pathological mechanisms underpinning the development of central nervous system disorders, most of them remain still unclear. In particular, the study of rare brain diseases is hurdled by the lack of post-mortem samples and of reliable epidemiological studies, thus the setting of in vitro modeling systems appears essential to dissect the puzzle of genetic and environmental alterations affecting neural cells viability and functionality The isolation and expansion in vitro of embryonic (ESC) and fetal neural stem cells (NSC) from human tissue has efficiently allowed to model several neurological diseases "in a dish" and has also provided a novel platform to test potential therapeutic strategies in a pre-clinical setting. In the recent years, the development of induced pluripotent stem cell (iPS) technology, has added enormous value to the aforementioned approach thanks to their capability for generating disease-relevant cell phenotypes in vitro and to their perspective use in autologous transplantation. However, while the potentiality of ESC, NSC and iPS has been widely sponsored, the pitfalls related to the available protocols for differentiation and the heterogeneity of lines deriving from different individuals have been poorly discussed. Here we present pro and contra of using ESC, NSC or iPS for modeling rare diseases like Lysosomal Storage disorders (LSDs) and Motor Neuron Syndromes (MNS). In this view, the advent of gene editing technologies is a unique opportunity to standardize the data analysis in preclinical studies and to tailor clinical protocols for stem cell-mediated therapy.

KW - Journal Article

U2 - 10.2174/1871527316666170615121753

DO - 10.2174/1871527316666170615121753

M3 - Article

C2 - 28641519

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

ER -